Generation and Immunity Testing of a Recombinant Adenovirus Expressing NcSRS2-NcGRA7 Fusion Protein of Bovine Neospora caninum.
10.3347/kjp.2013.51.2.247
- Author:
Li Jun JIA
1
;
Shou Fa ZHANG
;
Nian Chao QIAN
;
Xue Nan XUAN
;
Long Zheng YU
;
Xue Mei ZHANG
;
Ming Ming LIU
Author Information
1. Laboratory of Veterinary Microbiology, Department of Veterinary Medicine, Yanbian University, Yanji, Jilin Province 133002, People's Republic of China. lijunjia1015@sohu.com
- Publication Type:Brief Communication ; Research Support, Non-U.S. Gov't
- Keywords:
Neospora caninum;
bovine, NcSRS2-NcGRA7;
recombinant adenovirus, immunity
- MeSH:
Adenoviridae/*genetics;
Animals;
Antibodies, Fungal/blood;
Antigens, Fungal/genetics/*immunology;
*Drug Carriers;
Fungal Proteins/genetics/*immunology;
Fungal Vaccines/administration & dosage/genetics/*immunology;
Immunoglobulin G/blood;
Interferon-gamma/blood;
Interleukin-4/blood;
Mice;
Mice, Inbred BALB C;
Neospora/genetics/*immunology;
Recombinant Fusion Proteins/genetics/immunology;
Vaccines, Synthetic/administration & dosage/genetics/immunology
- From:The Korean Journal of Parasitology
2013;51(2):247-253
- CountryRepublic of Korea
- Language:English
-
Abstract:
Neospora caninum is the etiologic agent of bovine neosporosis, which affects the reproductive performance of cattle worldwide. The transmembrane protein, NcSRS2, and dense-granule protein, NcGRA7, were identified as protective antigens based on their ability to induce significant protective immune responses in murine neosporosis models. In the current study, NcSRS2 and NcGRA7 genes were spliced by overlap-extension PCR in a recombinant adenovirus termed Ad5-NcSRS2-NcGRA 7, expressing the NcSRS2-NcGRA7 gene, and the efficacy was evaluated in mice. The results showed that the titer of the recombinant adenovirus was 10(9)TCID50/ml. Three weeks post-boost immunization (w.p.b.i.), the IgG antibody titer in sera was as high as 1:4,096. IFN-gamma and IL-4 levels were significantly different from the control group (P<0.01). This research established a solid foundation for the development of a recombinant adenovirus vaccine against bovine N. caninum.
